T6427

Butein is a cAMP-specific PDE inhibitor, protein tyrosine kinase inhibitor, and SIRT1 activator. It sensitizes HeLa cells to Cisplatin by targeting FoxO3a via the AKT and ERK/p38 MAPK pathways.

Lutropin is a heterodimeric glycoprotein, a hormone produced by anterior pituitary gonadotrophs, which stimulates follicle development.

MAO-B-IN-6 is a selective, potent, orally active MAO-B inhibitor (IC50: 0.019 μM) and demonstrates superior efficacy to Safinamide both in vitro and in vivo.

MTL-CEPBA, a small activating RNA targeting C/EBPα upregulation, exhibits anti-inflammatory and anti-cancer effects.

Nampt-IN-10 TFA (compound 4) is a phosphoribosyltransferase (NAMPT) inhibitor with cellular efficacy against A2780 (IC50: 5 nM) and CORL23 (IC50: 19 nM), and can be used as a non-antimitotic payload for ADCs.

Neuraminidase-IN-11 (15e) is a selective and potent neuraminidase (NA) inhibitor, effective against the neuraminidase of H1N1 virus (IC50: 4.7 nM), H5N1 virus (IC50: 8.46 nM), and H5N8 virus (IC50: 1.5 nM).

Octanoyl coenzyme A lithium, a derivative of fatty acid acyl coenzyme A, inhibits citrate synthase and glutamate dehydrogenase (IC50: 0.4-1.6 mM).

ODN 2088 is an effective Toll-like receptor inhibitor exhibiting significant inhibitory activity against TLR3, TLR7, and TLR9 without cytotoxicity. It reduces IFN-α and IL-6 release by blocking associated innate immune signaling pathways. In vitro experiments demonstrated that ODN 2088 (0.01–10 μM, 48 hours) showed minimal inhibition of IL-6 release induced by CpG-ODN 2006 (100 nM), but markedly suppressed IL-6 secretion from human peripheral blood mononuclear cells stimulated by imiquimod (5 μg/mL). This demonstrates its differential regulatory potential across distinct TLR activation pathways.

ODN 21158 is a potent, non-cytotoxic inhibitor of G-modified TLR3 and TLR9. ODN 21158 dose-dependently inhibits IFN-α secretion.